进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

加利福尼亚州门洛帕克 - PacBio (NASDAQ:PACB)今日发布新闻稿宣布,任命Christopher Gibson博士加入其董事会。 Gibson是临床阶段生物技术公司Recursion (NASDAQ:RXRX)的联合创始人兼董事会主席。在Recursion,他领导开发了一个将生物数据生成与机器学习相结合的药物发现平台。他带领公司完成了募集资金、战略合作伙伴关系建立以及公开上市。 P ...

It's not looking too good for the biotech.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.